Champions Oncology, Inc. (CSBR)

USD 6.91

(7.97%)

Market Cap (In USD)

93.93 Million

Revenue (In USD)

50.15 Million

Net Income (In USD)

-7.27 Million

Avg. Volume

49.04 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
3.6-7.2199
PE
-
EPS
-
Beta Value
0.493
ISIN
US15870P3073
CUSIP
15870P307
CIK
771856
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Ronnie Morris M.D.
Employee Count
-
Website
https://www.championsoncology.com
Ipo Date
2007-02-02
Details
Champions Oncology, Inc. develops and sells technology solutions and products to personalize the development and use of oncology drugs in the United States. Its Tumorgraft Technology Platform is an approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. The company, through its Tumorgraft Technology Platform, provides personalized cancer care based upon the implantation of human tumors in immune-deficient mice. It also offers Translational Oncology Solutions that utilizes its technology platform to assist pharmaceutical and biotechnology companies with their drug development process. The company provides Lumin Bioinformatics, a software platform and data tool that contains comprehensive information derived from research services and clinical studies, and sold on an annual subscriptions basis. The company markets its products through internet, word of mouth, and sales force to patients and physicians. The company was formerly known as Champions Biotechnology, Inc. and changed its name to Champions Oncology, Inc. in April 2011. Champions Oncology, Inc. was incorporated in 1985 and is headquartered in Hackensack, New Jersey.